Evicenter
P&T meetings

Lonvoguran ziclumeran (lonvo-z)

Hereditary angioedema

Also known as NTLA-2002
Last updated
82 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Hereditary angioedema

Humanistic burden and health-related quality of life

3 evidence topics · 4 sources

Burden of disease in adults: multinational survey

“In the survey, participants reported 11.5 ± 14.2 HAE attacks (mean ± SD) in the past 6 months.” (opens the source at this quote in a new tab)

Multinational adult survey: treatment exposure and quality-of-life outcomes
MeasureReported result
Participants included“260”
Participants using any long-term prophylaxis“153 (58.8%)”
First-line prophylaxis among prophylaxis users, per study classification“56/153 (36.6%)”
AE-QoL total score, mean ± SD“42.9 ± 23.2”
Participants with AE-QoL total score ≥39“137 of 260 (52.7%)”
Moderate to severe anxiety by HADS“69 (26.5%)”
Moderate to severe depression by HADS“27 (10.4%)”
Patient preferences for long-term prophylaxis: discrete-choice experiment

“A reduction in attack frequency is the most important treatment feature for adults living with hereditary angioedema.” (opens the source at this quote in a new tab)